{
    "clinical_study": {
        "@rank": "36960", 
        "arm_group": {
            "arm_group_label": "Extracorporeal Photopheresis", 
            "arm_group_type": "Experimental", 
            "description": "Extracorporeal Photopheresis"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety of photopheresis for prophylaxis of\n      allograft rejection in patients who are being withdrawal immunosuppression after liver\n      transplantation."
        }, 
        "brief_title": "Extracorporeal Photopheresis After Liver Transplant", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatic Insufficiency", 
        "condition_browse": {
            "mesh_term": "Hepatic Insufficiency"
        }, 
        "detailed_description": {
            "textblock": "The photopheresis (ECP) is a therapeutic approach based on the biological effect of\n      ultraviolet light A on mononuclear cells collected by apheresis, and reinfused into the\n      patient."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Liver transplantation 2 years ago\n\n          -  >18 years\n\n          -  Treatment with immunosuppression (Cyclosporine or tacrolimus)\n\n          -  Normal hepatic function during last year\n\n          -  No acute or chronic rejection\n\n          -  to have some secondary effect because of immunosuppressors\n\n          -  Previous disease: alcoholic liver cirrhosis with or without hepatocarcinoma,\n             metabolic disease, amyloid polyneuropathy, hepatitis,cryptogenic cirrhosis and non\n             autoimmune causes\n\n          -  Signing consent informed form\n\n        Exclusion Criteria:\n\n          -  Additional liver Transplantation\n\n          -  hypersensitivity to methoxsalen\n\n          -  Patients with melanoma ,cutaneous carcinoma\n\n          -  Patients with aphakia\n\n          -  Patients treated with oxsoralen\n\n          -  Pregnant women, lactating women or fertile adults that they don\u00b4t use a effective\n             anticonception method\n\n          -  Involved in other assay."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02090621", 
            "org_study_id": "FEC-TH", 
            "secondary_id": "2012-000633-39"
        }, 
        "intervention": {
            "arm_group_label": "Extracorporeal Photopheresis", 
            "description": "Extracorporeal photopheresis with Methoxsalen(UVADEX)and immunosuppression reduction Extracorporeal photopheresis (ECP) is an immunomodulatory excellent technical tolerated initially designed for the treatment of cutaneous T-cell lymphoma and various autoimmune diseases, which has been proven effective in reversing episodes acute heart transplants, kidney and lung rejection, and in the treatment of Disease graft versus host both acute and chronic.", 
            "intervention_name": "Extracorporeal photopheresis", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Liver", 
            "transplantation", 
            "Immunosuppression", 
            "photopheresis", 
            "extracorporeal"
        ], 
        "lastchanged_date": "March 18, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Murcia", 
                    "country": "Spain", 
                    "state": "El Palmar", 
                    "zip": "30120"
                }, 
                "name": "Jose Antonio Pons, MD"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "official_title": "Extracorporeal Photopheresis After Liver Transplant. Phase II Clinical Trial on Safety and Efficacy in Patients With Progressive Withdrawal of Immunosuppression", 
        "overall_contact": {
            "email": "joseapons@yahoo.es", 
            "last_name": "Jose Antonio Pons, MD"
        }, 
        "overall_official": {
            "affiliation": "Hospital Cl\u00ednco Universitario Virgen de la Arrixaca", 
            "last_name": "Jose Antonio Pons, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Serious Adverse Events associated with the procedure", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Non Serious Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Allograft Rejection", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "reference": [
            {
                "PMID": "12698096", 
                "citation": "Pons JA, Y\u00e9lamos J, Ram\u00edrez P, Oliver-Bonet M, S\u00e1nchez A, Rodr\u00edguez-Gago M, Navarro J, Bermejo J, Robles R, Parrilla P. Endothelial cell chimerism does not influence allograft tolerance in liver transplant patients after withdrawal of immunosuppression. Transplantation. 2003 Apr 15;75(7):1045-7."
            }, 
            {
                "PMID": "19210687", 
                "citation": "Pons JA, Ram\u00edrez P, Revilla-Nuin B, Pascual D, Baroja-Mazo A, Robles R, Sanchez-Bueno F, Martinez L, Parrilla P. Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients. Clin Transplant. 2009 Jun-Jul;23(3):329-36. doi: 10.1111/j.1399-0012.2008.00944.x. Epub 2009 Feb 5."
            }, 
            {
                "PMID": "19034005", 
                "citation": "Pons JA, Revilla-Nuin B, Baroja-Mazo A, Ram\u00edrez P, Mart\u00ednez-Alarc\u00f3n L, S\u00e1nchez-Bueno F, Robles R, Rios A, Aparicio P, Parrilla P. FoxP3 in peripheral blood is associated with operational tolerance in liver transplant patients during immunosuppression withdrawal. Transplantation. 2008 Nov 27;86(10):1370-8. doi: 10.1097/TP.0b013e318188d3e6."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02090621"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "CyA, tacrolimus levels", 
                "measure": "Immunosuppressant level", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Total protein, albumin, bilirubin, GOT, GPT, alkaline phosphatase, gamma- GT, Quick index.", 
                "measure": "Liver function test", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Creatinine, urea, glomerular filtration rate (MDRD), creatinine clearance", 
                "measure": "Renal Function test", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Basic hematological parameters:\nHemoglobin, hematocrit, platelets and leukocytes.\nMetabolic parameters:\nGlucose, uric acid, triglycerides, cholesterol, HDL and LDL cholesterol.", 
                "measure": "Hematological Parameters", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Study of the evolution of subpopulations of blood mononuclear cells peripheral (T cells, B cells and dendritic cells) During removal of the SI measured by flow cytometry of different lymphocyte populations and are expressed as% and / or item # cells / L blood", 
                "measure": "Immunological evaluation", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}